PubMed · 9558001
Tumor antigen presentation: changing the rules.
Abstract
Cell-based tumor vaccines have been developed on the basis of the hypothesis that tumor cells can be genetically modified to present antigen to T lymphocytes directly. Contrary to expectations, cross-priming is the predominant pathway for activation of tumor-specific CD8+ T cells, while direct presentation of antigen dominates activation of tumor-specific CD4+ T cells. These results pose interesting paradoxes for the generation of immune responses, and have definite implications for the development of anti-cancer vaccines.
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
T D Armstrong, B A Pulaski, S Ostrand-Rosenberg. 1998. Tumor antigen presentation: changing the rules.. https://doi.org/10.1007/s002620050463
Cite the original work for its findings. Save a collection to share your selection of sources.